Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II (VECTORII)

This study has been completed.
UMC Utrecht
Information provided by (Responsible Party):
Radboud University Identifier:
First received: January 4, 2013
Last updated: November 27, 2014
Last verified: November 2014

Excessive inflammation is associated with tissue damage caused by over-activation of the innate immune system. This can range from mild disease to extreme conditions, such as multiple organ dysfunction syndrome (MODS) and acute respiratory distress (ARDS). In marked contrast to adaptive immunity which is very sensitive to immune modulators such as steroids, the innate immune system cannot be sufficiently targeted by currently available anti-inflammatory drugs.

The investigators hypothesize that pre-treatment with C1-esterase inhibitor in a human endotoxemia model can modulate the innate immune response.

In this study, human endotoxemia will be used as a model for inflammation. Subjects will, prior to endotoxin administration, receive C1 esterase inhibitor or placebo. Blood will be sampled to determine the levels of markers of the innate immune response.

Condition Intervention Phase
Innate Immune Response
Drug: C1-esterase inhibitor
Drug: Endotoxin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Neutrophil phenotype and redistribution [ Time Frame: 8 hrs after LPS administration ]

Secondary Outcome Measures:
  • Cytokines and other markers of inflammation [ Time Frame: 8 hrs after LPS administration ]
  • C1-inhibitor and complement concentration and activity [ Time Frame: 8 hrs after LPS administration ]

Enrollment: 20
Study Start Date: September 2013
Study Completion Date: January 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: C1-esterase inhibitor
C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
Drug: C1-esterase inhibitor
Other Name: Cetor
Drug: Endotoxin
Other Name: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative
Placebo Comparator: Placebo
Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
Drug: Endotoxin
Other Name: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers (18-35 years old)

Exclusion Criteria:

  • Relevant medical history
  • Drug-, nicotine-abuses
  • Tendency towards fainting
  • Hyper- or hypotension
  • Use of any medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01766414

Radboud University
Nijmegen, Netherlands
Sponsors and Collaborators
Radboud University
UMC Utrecht
Study Director: Hans Hoeven, Prof UMC Nijmegen
  More Information

Responsible Party: Radboud University Identifier: NCT01766414     History of Changes
Other Study ID Numbers: 36688
2011-002222-46 ( EudraCT Number )
Study First Received: January 4, 2013
Last Updated: November 27, 2014

Additional relevant MeSH terms:
Pathologic Processes
Systemic Inflammatory Response Syndrome
Complement C1s
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Immunologic Factors
Physiological Effects of Drugs
Complement Inactivating Agents
Immunosuppressive Agents processed this record on May 25, 2017